Salbutamol active pharmaceutical ingredient (API) Global Market Report 2025

The salbutamol active pharmaceutical ingredient (API) market size has grown strongly in recent years. It will grow from $2.86 billion in 2024 to $3.05 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The expansion during the historical period was supported by a growing prevalence of respiratory illnesses, an aging demographic, increased availability of generic medications, a rise in healthcare infrastructure, and heightened levels of environmental pollution.

The salbutamol active pharmaceutical ingredient (API) market size is expected to see strong growth in the next few years. It will grow to $3.9 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The projected growth is attributed to worsening air quality, increasing rates of asthma and COPD, escalating demand for generics, growing healthcare spending, and the development of healthcare infrastructure. Prominent trends anticipated in the coming years include progress in eco-friendly chemical processes, greater adoption of automated production systems, enhanced use of process analytical technology (PAT), innovations in metered-dose inhaler technologies, and the emergence of individualized dosing formats.

The rising incidence of respiratory diseases is expected to drive the growth of the salbutamol active pharmaceutical ingredient (API) market in the coming years. Respiratory conditions affect the lungs and airways, leading to breathing difficulties and reduced oxygen intake. These conditions include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and other lung infections. The growing number of respiratory cases is largely attributed to increasing air pollution, which exposes individuals to harmful pollutants that irritate the airways and impair lung function. Salbutamol API plays a vital role in treating these conditions by helping to open the airways, providing quick relief from symptoms such as wheezing and shortness of breath, and improving overall respiratory function and patient health. For example, in November 2024, the Australian Bureau of Statistics reported that in 2022, approximately 2.8 million Australians - about 11% of the population - were living with asthma. Asthma accounted for 2.5% of the total disease burden and 35% of the respiratory disease burden in 2023, making it the leading cause of disease burden among children aged 1-9 years. Consequently, the increasing prevalence of respiratory diseases is fueling the demand for salbutamol API.

Companies operating in the salbutamol API market are increasingly focusing on innovative drug formulations, such as eco-friendly inhalers, to align with environmental standards and offer sustainable treatment solutions. These inhalers utilize propellants with low global warming potential or are designed as propellant-free systems, such as dry powder inhalers. For instance, in November 2023, GSK plc, a UK-based pharmaceutical company, advanced its low-carbon Ventolin inhaler to Phase III trials. This inhaler uses a next-generation propellant that reduces emissions by 90%. Ventolin is a brand of inhalers containing salbutamol (also known as albuterol), which works by opening the airways to provide relief from asthma and other respiratory issues. The company’s sustainability initiative focuses on modifying the propellant used in the inhaler to reduce its environmental impact, while maintaining the same active ingredient - salbutamol API.

In October 2022, Lupin Limited, an India-based pharmaceutical company, acquired the rights to Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol from Sunovion Pharmaceuticals Inc. for $75 million. This acquisition enhances Lupin’s respiratory product portfolio in the US market, strengthening its presence in the inhalation therapy segment and improving its capability to support patients with chronic respiratory conditions. Sunovion Pharmaceuticals Inc. is a US-based firm known for its expertise in respiratory treatments, including those based on the salbutamol active pharmaceutical ingredient (API) for asthma and COPD.

Major players in the salbutamol active pharmaceutical ingredient (api) market are Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Limited, Amphastar Pharmaceuticals Inc., FDC Limited, Neuland Laboratories Ltd., Melody Healthcare Pvt. Ltd., Supriya Lifescience Ltd., Lusochimica S.p.A., Intas Pharmaceuticals ltd, Olon S.p.A., VIVAN Life Sciences, Vamsi Labs Ltd., Aarti Pharmalabs Ltd., Jayco Chemical Industries, Orex Pharma Pvt. Ltd., Enomark, Chemcopia, and Cerata Pharma.

North America was the largest region in the salbutamol active pharmaceutical ingredient (API) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in salbutamol active pharmaceutical ingredient (API) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the salbutamol active pharmaceutical ingredient (API) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Salbutamol active pharmaceutical ingredient (API) is the pure, pharmacologically active component that delivers the intended therapeutic effect in medications used for treating respiratory disorders. It serves as the foundational compound utilized by pharmaceutical manufacturers in producing finished dosage forms such as inhalers, tablets, and syrups.

The primary variants of salbutamol active pharmaceutical ingredient (API) include salbutamol sulfate and levalbuterol hydrochloride. Salbutamol sulfate, the sulfate salt form of salbutamol, acts as a rapid-onset bronchodilator, alleviating symptoms of asthma and other obstructive airway conditions by relaxing airway muscles. These APIs are formulated into inhalation solutions, tablets, syrups, and other dosage forms and are made available through hospital pharmacies, retail pharmacies, and online platforms. They are indicated for conditions such as asthma, chronic obstructive pulmonary disease (COPD), bronchospasm, among others, and are used by end-users like pharmaceutical companies, research institutions, and others.

The salbutamol active pharmaceutical ingredient (API) market research report is one of a series of new reports that provides salbutamol active pharmaceutical ingredient (API) market statistics, including the salbutamol industry global market size, regional shares, competitors with the salbutamol active pharmaceutical ingredient (API) market share, detailed salbutamol active pharmaceutical ingredient (API) market segments, market trends, and opportunities, and any further data you may need to thrive in the salbutamol active pharmaceutical ingredient (API) industry. This salbutamol active pharmaceutical ingredient (API) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The salbutamol active pharmaceutical ingredient (API) market consists of sales of nebulizer solutions, raw salbutamol powder, and injectable salbutamol formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.